Celsion, Corp. (NASDAQ:CLSN) Up 30% Following Announcement of Continuing Positive Data From OVATION Study

Celsion, Corp. (NASDAQ:CLSN) Up 30% Following Announcement of Continuing Positive Data From OVATION Study

Fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies, Celsion, Corp. (NASDAQ:CLSN), announces more positive data from their OVATION study to enthusiastic investors. Fourth Cohort of Patients Continues to Show Clinically Meaningful Responses in the Evaluation of GEN-1, A Novel IL-12 DNA-based Immunotherapy, in Combination with the Standard of Care LAWRENCEVILLE, N.J., Jan. 17, 2017 (GLOBE NEWSWIRE) — […]

Read More ˃